Ultragenyx Pharmaceutical (RARE) Inventory (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Inventory for 10 consecutive years, with $55.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory rose 19.48% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (up 19.48% YoY), while the FY2025 annual figure was $52.0 million, up 15.56% from the prior year.
• Inventory rose to $55.0 million in Q1 2026 per RARE's latest filing, from $52.0 million in the prior quarter.
• Across five years, Inventory topped out at $55.0 million in Q1 2026 and bottomed at $17.8 million in Q1 2022.
• Historically, Inventory has averaged $36.7 million across 5 years, with a median of $35.9 million in 2024.
• Annual changes were most pronounced in 2022 — Inventory soared 64.91% — and 2025, when it rose 15.56%.
• Ultragenyx Pharmaceutical's Inventory stood at $26.8 million in 2022, then climbed by 26.91% to $34.0 million in 2023, then jumped by 32.47% to $45.0 million in 2024, then climbed by 15.56% to $52.0 million in 2025, then grew by 5.77% to $55.0 million in 2026.
• Business Quant data shows RARE's Inventory at $55.0 million in Q1 2026, $52.0 million in Q4 2025, and $52.2 million in Q3 2025.